FIBRILLIN ABNORMALITIES AND PROGNOSIS IN MARFAN-SYNDROME AND RELATED DISORDERS

被引:61
作者
AOYAMA, T
FRANCKE, U
GASNER, C
FURTHMAYR, H
机构
[1] STANFORD UNIV,MED CTR,DEPT GENET,STANFORD,CA 94305
[2] STANFORD UNIV,MED CTR,DEPT CARDIOVASC MED,STANFORD,CA 94305
[3] STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305
来源
AMERICAN JOURNAL OF MEDICAL GENETICS | 1995年 / 58卷 / 02期
关键词
MARFAN SYNDROME; ABNORMAL FIBRILLIN; MUTATIONS; PULSE CHASE STUDIES; PROGNOSIS; DIAGNOSIS;
D O I
10.1002/ajmg.1320580216
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Marfan syndrome (MFS), a multisystem autosomal-dominant disorder, is characterized by mutations of the fibrillin-1 (FBN1) gene and by abnormal patterns of synthesis, secretion, and matrix deposition of the fibrillin protein. To determine the;sensitivity and specificity of fibrillin protein abnormalities in the diagnosis of MFS, we studied dermal fibroblasts from 57 patients with classical MFS, 15 with equivocal MFS, 8 with single-organ manifestations, anti 16 with other connective tissue disorders including homocystinuria and Ehlers-Danlos syndrome. Abnormal fibrillin metabolism was identified in 70 samples that were classified into four different groups based on quantitation of fibrillin synthesis and matrix deposition. Significant correlations were found for phenotypic features including arachn odactyly, striae distensae, cardiovascular manifestations, and fibrillin groups II and IV, which included 70% of the MFS patients. In addition, these two groups were associated with shortened ''event-free'' survival and more severe cardiovascular complications than groups I and III. The latter included most of the equivocal MFS/single manifestation patients with fibrillin abnormalities. Our results indicate that fibrillin defects at the protein level per se are not specific for MFS, but that the drastically reduced fibrillin deposition, caused by a dominant-negative effect of abnormal fibrillin molecules in individuals defined as groups II and IV, is of prognostic and possibly diagnostic significance. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:169 / 176
页数:8
相关论文
共 22 条
[11]   A NOVEL FIBRILLIN MUTATION IN THE MARFAN-SYNDROME WHICH COULD DISRUPT CALCIUM-BINDING OF THE EPIDERMAL GROWTH FACTOR-LIKE MODULE [J].
HEWETT, DR ;
LYNCH, JR ;
SMITH, R ;
SYKES, BC .
HUMAN MOLECULAR GENETICS, 1993, 2 (04) :475-477
[12]   IMMUNOHISTOLOGIC ABNORMALITIES OF THE MICROFIBRILLAR-FIBER SYSTEM IN THE MARFAN-SYNDROME [J].
HOLLISTER, DW ;
GODFREY, M ;
SAKAI, LY ;
PYERITZ, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (03) :152-159
[13]   2 MUTATIONS IN MARFAN-SYNDROME RESULTING IN TRUNCATED FIBRILLIN POLYPEPTIDES [J].
KAINULAINEN, K ;
SAKAI, LY ;
CHILD, A ;
POPE, FM ;
PUHAKKA, L ;
RYHANEN, L ;
PALOTIE, A ;
KAITILA, I ;
PELTONEN, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (13) :5917-5921
[14]   MUTATIONS IN THE FIBRILLIN GENE RESPONSIBLE FOR DOMINANT ECTOPIA LENTIS AND NEONATAL MARFAN-SYNDROME [J].
KAINULAINEN, K ;
KARTTUNEN, L ;
PUHAKKA, L ;
SAKAI, L ;
PELTONEN, L .
NATURE GENETICS, 1994, 6 (01) :64-69
[15]   LINKAGE OF MARFAN-SYNDROME AND A PHENOTYPICALLY RELATED DISORDER TO 2 DIFFERENT FIBRILLIN GENES [J].
LEE, B ;
GODFREY, M ;
VITALE, E ;
HORI, H ;
MATTEI, MG ;
SARFARAZI, M ;
TSIPOURAS, P ;
RAMIREZ, F ;
HOLLISTER, DW .
NATURE, 1991, 352 (6333) :330-334
[16]   A NOVEL MUTATION OF THE FIBRILLIN GENE CAUSING ECTOPIA LENTIS [J].
LONNQVIST, L ;
CHILD, A ;
KAINULAINEN, K ;
DAVIDSON, R ;
PUHAKKA, L ;
PELTONEN, L .
GENOMICS, 1994, 19 (03) :573-576
[17]  
MCGOOKEYMILEWIC.D, 1992, J CLIN INVEST, V89, P79
[18]  
MILEWICZ DM, 1994, AM J HUM GENET, V54, P447
[19]   A MOLECULAR APPROACH TO THE STRATIFICATION OF CARDIOVASCULAR RISK IN FAMILIES WITH MARFANS-SYNDROME [J].
PEREIRA, L ;
LEVRAN, O ;
RAMIREZ, F ;
LYNCH, JR ;
SYKES, B ;
PYERITZ, RE ;
DIETZ, HC .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (03) :148-153
[20]   PROGRESSION OF AORTIC DILATATION AND THE BENEFIT OF LONG-TERM BETA-ADRENERGIC-BLOCKADE IN MARFANS-SYNDROME [J].
SHORES, J ;
BERGER, KR ;
MURPHY, EA ;
PYERITZ, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (19) :1335-1341